Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) Receives Average Recommendation of “Buy” from Analysts

Shares of Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) have earned a consensus recommendation of “Buy” from the seven brokerages that are currently covering the company, MarketBeat reports. Six equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. The average twelve-month price objective among analysts that have issued ratings on the stock in the last year is $5.20.

A number of brokerages recently issued reports on RVPH. Maxim Group lowered their price objective on Reviva Pharmaceuticals from $5.00 to $2.00 and set a “buy” rating on the stock in a research report on Friday, August 15th. Wall Street Zen upgraded Reviva Pharmaceuticals to a “sell” rating in a research report on Saturday, August 16th. Citigroup reiterated a “buy” rating on shares of Reviva Pharmaceuticals in a research report on Friday, August 15th. D. Boral Capital reiterated a “buy” rating and set a $3.00 target price on shares of Reviva Pharmaceuticals in a research report on Monday, August 18th. Finally, Roth Capital reiterated a “buy” rating and set a $3.00 target price (down from $7.00) on shares of Reviva Pharmaceuticals in a research report on Monday, August 18th.

Institutional Investors Weigh In On Reviva Pharmaceuticals

Several hedge funds have recently bought and sold shares of the stock. 683 Capital Management LLC bought a new stake in Reviva Pharmaceuticals during the second quarter valued at approximately $381,000. Armistice Capital LLC bought a new stake in Reviva Pharmaceuticals during the second quarter valued at approximately $1,026,000. XTX Topco Ltd bought a new stake in shares of Reviva Pharmaceuticals in the 2nd quarter worth approximately $31,000. Persistent Asset Partners Ltd boosted its stake in shares of Reviva Pharmaceuticals by 300.0% in the 2nd quarter. Persistent Asset Partners Ltd now owns 641,174 shares of the company’s stock valued at $244,000 after purchasing an additional 480,864 shares in the last quarter. Finally, Geode Capital Management LLC boosted its stake in shares of Reviva Pharmaceuticals by 6.9% in the 2nd quarter. Geode Capital Management LLC now owns 448,202 shares of the company’s stock valued at $171,000 after purchasing an additional 29,063 shares in the last quarter. 63.18% of the stock is currently owned by institutional investors.

Reviva Pharmaceuticals Trading Down 0.1%

Shares of NASDAQ:RVPH opened at $0.46 on Friday. The company has a 50 day moving average of $0.46 and a 200 day moving average of $0.81. The stock has a market cap of $31.30 million, a P/E ratio of -0.71 and a beta of -0.05. Reviva Pharmaceuticals has a 12 month low of $0.30 and a 12 month high of $4.28.

Reviva Pharmaceuticals (NASDAQ:RVPH) last released its quarterly earnings results on Thursday, August 14th. The company reported ($0.12) EPS for the quarter, beating analysts’ consensus estimates of ($0.15) by $0.03. On average, equities analysts forecast that Reviva Pharmaceuticals will post -0.97 earnings per share for the current fiscal year.

About Reviva Pharmaceuticals

Reviva Pharmaceuticals Holdings, Inc, a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of various neuropsychiatric indications, including schizophrenia, bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer's disease, and Parkinson's disease psychosis; in clinical development respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis; and in preclinical development for the treatment of psoriasis.